NASDAQ$HOWL

Werewolf Therapeutics Inc · Q4 2024 earnings

Q4 2024 earnings · · Before market open · Investor relations

Briefing

Werewolf Therapeutics reported Q4 2024 revenue of $1.5M, a net loss of $20.4M.

For Q4 2024, Werewolf Therapeutics reported Revenue was $1.5M, net loss was $20.4M. Management discusses segment trends, liquidity, and outlook in the quarterly filing.

  • Revenue $1.5M for Q4 2024.
  • Net loss $20.4M.
  • MD&A highlights operating priorities, liquidity, and sector risks.

Headline financials

Total Revenue

$1.5M

Previous: $1.5M-0.1%
EPS (adj)

-$0.46

Previous: -$0.33-39.4%
Collaboration Revenue

$0.00

No prior period
R&D Expenses

$15.7K

No prior period
G&A Expenses

$4.62K

No prior period
Total Operating Expenses

$20.3K

No prior period
Other Expense

-$52.00

No prior period
Net Loss Per Share (Basic)

-$0.46

No prior period
Net Loss Per Share (Diluted)

-$0.46

No prior period
Wtd Avg Shares Outstanding (Basic)

44.5M

No prior period
Wtd Avg Shares Outstanding (Diluted)

44.5M

No prior period
Total Stockholders’ Equity

$73.4K

No prior period
Total Notes Payable (Net)

$26.1K

No prior period
Capital Expenditures

-$123K

Previous: -$198K+37.9%
Net Income

-$20.4M

Previous: -$12M-70.0%
Operating Income

-$20.3K

Previous: -$13M+99.8%
Gross Profit

-$442K

Previous: $1.04M-142.5%
R&D Expense

$15.7M

Previous: $9.65M+63.0%

Revenue & EPS history

Werewolf Therapeutics · Revenue · Quarterly

$1.5M

Q4 2024-0.1%vs Q4 2023
Beat estimate in 4 of 12 quarters(33%)
ActualEstimate

Forward guidance

Outlook emphasizes clinical milestones, liquidity runway, and operating expense discipline.

Tailwinds

  • Pipeline progress and partnership economics.
  • Cash supports near-term operating plans.

Headwinds

  • Operating losses until commercial scale.
  • Financing and trial outcomes affect funding costs.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+0.1%

Avg return

Earnings day

-0.8%

Avg return

5 days after

+2.2%

Avg return

30 days after

52%

12 / 23 earnings

Positive

+16.5%

Q2 2022

Best reaction

-7.4%

Q4 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-3.5%-2.3%-39.8%
Q3 2025-5.0%-7.4%-22.0%
Q2 2025-1.5%-5.9%+5.9%
Q1 2025+0.9%-2.7%+9.9%
Q4 2024-0.9%-3.4%-21.5%
Q3 2024-5.7%-11.9%-26.2%
Q1 2024-1.6%-9.9%-15.0%
Q4 2023-7.4%-6.1%-15.8%
Q3 2023-0.9%+3.6%+28.8%
Q2 2023+3.2%-0.8%-0.4%
Q1 2023-3.3%-9.9%+11.2%
Q4 2022+6.1%+9.2%+3.1%
Q3 2022+2.3%-5.0%-19.4%
Q2 2022+16.5%+21.3%+55.2%
Q1 2022+3.3%-12.1%+1.7%
Q4 2021+0.5%+9.5%+12.6%
Q3 2021+1.8%+1.6%-6.7%
Q3 2020+1.8%+1.6%-6.7%
Q2 2021-3.5%-2.7%+13.9%
Q2 2020-3.5%-2.7%+13.9%
Q1 2021+1.0%+5.8%+22.4%
Q1 2020+1.0%+5.8%+22.4%
Q4 2020+1.0%+5.8%+22.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro